MedTrace Logo

Differences in Flare Reaction Incidence and Intensity Following Trigger Finger Injections

NCT04900220 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2023-06-23

Study results available
· View outcomes & findings →

Summary

Two common corticosteroids used for trigger finger treatment are betamethasone and methylprednisolone. Both injections are effective in treating trigger finger and the decision of which to use in treatment is currently a matter of the current practice and physician preference. The goal through this randomized trial is to see whether there is a difference between these two corticosteroids in inducing flare reactions and if there are any differences in the peak level of pain and their duration. Findings indicating a statistically significant difference in the incidence and/or intensity of the flare reactions would be clinically significant and would be evidence supporting the switch of current practice to one corticosteroid over the other.

Conditions

  • Trigger Finger

Interventions

DRUG

Betamethasone

The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of betamethasone (6 mg)

DRUG

Methylprednisolone

The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)

Sponsors & Collaborators

  • West Virginia University

    lead OTHER

Principal Investigators

  • Shatic Sraj, MD · West Virginia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-15
Primary Completion
2022-12-27
Completion
2023-04-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04900220 on ClinicalTrials.gov